Cargando…

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) occurs in 10–15% of all breast cancer patients, yet it accounts for about half of all breast cancer deaths. There is an urgent need to identify new antitumor targets to provide additional treatment options for patients afflicted with this aggressive disease. Prec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamilton, Nalo, Austin, David, Márquez-Garbán, Diana, Sanchez, Rudy, Chau, Brittney, Foos, Kay, Wu, Yanyuan, Vadgama, Jaydutt, Pietras, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713274/ https://www.ncbi.nlm.nih.gov/pubmed/29099049 http://dx.doi.org/10.3390/ijms18112305

Ejemplares similares

Biologic Roles of Estrogen Receptor-β and Insulin-Like Growth Factor-2 in Triple-Negative Breast Cancer
por: Hamilton, Nalo, et al.
Publicado: (2015)

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment
por: Austin, David, et al.
Publicado: (2018)

Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression
por: Sterling, Colin, et al.
Publicado: (2022)

GROα overexpression drives cell migration and invasion in triple negative breast cancer cells
por: Bhat, Kruttika, et al.
Publicado: (2017)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN
por: Wu, Yanyuan, et al.
Publicado: (2013)

Novel Metformin Analogues for Treatment of Pancreatic Cancer
por: Burton, Lorena P, et al.
Publicado: (2021)

Epithelial-Mesenchymal Transition and Breast Cancer
por: Wu, Yanyuan, et al.
Publicado: (2016)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

From Interaction to Intervention: How Mesenchymal Stem Cells Affect and Target Triple-Negative Breast Cancer
por: Wu, Yong, et al.
Publicado: (2023)

AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
por: Cao, Wei, et al.
Publicado: (2019)

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits
por: CHUNG, SEYUNG S., et al.
Publicado: (2013)

Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies
por: Hao, Qiongyu, et al.
Publicado: (2022)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

Genetic variants in African-American and Hispanic patients with breast cancer
por: Dutta, Pranabananda, et al.
Publicado: (2022)

Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice
por: Wu, Yanyuan, et al.
Publicado: (2014)

Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women
por: Wu, Yanyuan, et al.
Publicado: (2017)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer
por: Dutta, Pranabananda, et al.
Publicado: (2020)

Tumor-Derived Exosomes in Tumor-Induced Immune Suppression
por: Hao, Qiongyu, et al.
Publicado: (2022)

A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells
por: Wu, Yanyuan, et al.
Publicado: (2017)

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
por: Wu, Yanyuan, et al.
Publicado: (2010)

The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
por: Elshimali, Yahya I., et al.
Publicado: (2013)

Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance
por: Nava, Miguel, et al.
Publicado: (2019)

Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women
por: Wu, Yanyuan, et al.
Publicado: (2022)

IGF-1 Regulates Cyr61 Induced Breast Cancer Cell Proliferation and Invasion
por: Sarkissyan, Suren, et al.
Publicado: (2014)

SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer
por: Young, Patricia A, et al.
Publicado: (2020)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
por: Wu, Yanyuan, et al.
Publicado: (2008)

Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets
por: Nava, Miguel, et al.
Publicado: (2019)

Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis
por: Liu, Dingxie, et al.
Publicado: (2021)

Constitutive Activation of STAT3 Signaling Regulates hTERT and Promotes Stem Cell-Like Traits in Human Breast Cancer Cells
por: Chung, Seyung S., et al.
Publicado: (2013)

RF19 | PSUN344 Control of Androgen Signaling and Metastasis by CARF in Prostate Cancer
por: Hasan, Kamrul, et al.
Publicado: (2022)

Optimization Of Cancer Treatment Through Overcoming Drug Resistance
por: Elshimali, Yahya I., et al.
Publicado: (2018)

Roles of Protein Disulfide Isomerase in Breast Cancer
por: Yang, Suhui, et al.
Publicado: (2022)

Advancing Cancer Research: Insights and Innovations in Pathogenesis and Targeted Therapies
por: Wu, Yong, et al.
Publicado: (2023)

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer
por: Brumec, Maša, et al.
Publicado: (2021)

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
por: Khadela, Avinash, et al.
Publicado: (2022)

Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
por: Asano, Yuka, et al.
Publicado: (2017)

Targeting the androgen receptor in triple-negative breast cancer: current perspectives
por: Mina, Alain, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bbgbdtqej71esb4osmpitkv585